ADULT ORAL Updated: August 14, 2018

Regimen Reference Order – LYMP – iBRUtinib

ARIA: LYMP - [iBRUtinib (Mantle Cell)]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Mantle Cell Lymphoma

Proceed with treatment if:

ANC equal to or greater than 0.5 x $10^9/L$ AND Platelets equal to or greater than 25 x $10^9/L$

Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
allopurinol*	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles		
		* Only patients at risk of tumor lysis syndrome will be prescribed allopurinol		

Treatment Regimen – LYMP – iBRUtinib				
Drug	Dose	CCMB Administration Guideline		
iBRUtinib	560 mg	Orally once daily (with or without food) (Self-administered at home)		
BRUtinib (Imbruvica Classification: Cytot	a®) available dosage streng	gth: 140 mg capsule		

REQUIRED MONITORING

- CBC, biochemistry once weekly for 4 weeks then prior to each cycle thereafter as per physician order
- Monitor pulse for tachycardia and irregular rhythm at each clinic visit
- Order EKG to assess for atrial fibrillation if tachycardia or irregular rhythm present

Recommended Support Medications				
	Drug	Dose	CCMB Administration Guideline	
Not Applicable				

INSTRUCTIONS FOR PATIENT

- Patients should notify clinic prior to starting any new medication. iBRUtinib has potential for drug-drug interactions
- Avoid grapefruit and grapefruit juice
- Patient should report bleeding, palpitations, syncope, and skin or nail changes
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on iBRUtinib



ADULT ORAL LYMP - iBRUtinib

ADDITIONAL INFORMATION

• Lymphocytosis is expected with therapy and will not be considered evidence of disease progression unless accompanied by other clinical signs of disease progression (i.e. increasing lymphadenopathy, constitutional symptoms, etc.)

• iBRUtinib will be dispensed by CancerCare Manitoba Pharmacy

